Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab by Mototsugu Matsunaga, Keisuke Miwa, Yosuke Oka, Sachiko Nagasu, Takahiko Sakaue, Masaru Fukahori, Tomoyuki Ushijima, Yoshito Akagi

Get full text

Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults by Kohei Kometani, Takaaki Yorimitsu, Takaaki Yorimitsu, Norihide Jo, Norihide Jo, Erina Yamaguchi, Osamu Kikuchi, Osamu Kikuchi, Osamu Kikuchi, Masaru Fukahori, Masaru Fukahori, Takeshi Sawada, Takeshi Sawada, Yoshitaka Tsujimoto, Yoshitaka Tsujimoto, Ayana Sunami, Ayana Sunami, Mengqian Li, Takeshi Ito, Yann Pretemer, Yuxian Gao, Yuxian Gao, Yu Hidaka, Masaki Yamamoto, Natsuko Kaku, Natsuko Kaku, Yu Nakagama, Yu Nakagama, Yasutoshi Kido, Yasutoshi Kido, Alba Grifoni, Alessandro Sette, Alessandro Sette, Miki Nagao, Satoshi Morita, Takako E. Nakajima, Takako E. Nakajima, Manabu Muto, Manabu Muto, Manabu Muto, Yoko Hamazaki, Yoko Hamazaki, Yoko Hamazaki

Get full text

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-pa... by Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba

Get full text

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel by Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba

Get full text

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer by Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa

Get full text

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel by Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text